ACTU
Actuate Therapeutics Inc.

116
Mkt Cap
$56.71M
Volume
69,083.00
52W High
$11.99
52W Low
$2.27
PE Ratio
-2.02
ACTU Fundamentals
Price
$2.21
Prev Close
$2.44
Open
$2.42
50D MA
$4.14
Beta
0.93
Avg. Volume
36,705.80
EPS (Annual)
-$1.40
P/B
5.19
Rev/Employee
$0.00
$147.24
Loading...
Loading...
News
all
press releases
Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU
Voss Capital LP raised its holdings in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 213.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Actuate Therapeutics (NASDAQ:ACTU) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded shares of Actuate Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·17d ago
News Placeholder
Actuate Therapeutics (NASDAQ:ACTU) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Actuate Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y
MTD beats Q4 estimates as adjusted EPS jumps 8% Y/Y and sales rise to $1.13B, led by solid growth across Laboratory, Industrial and Food Retail.
Zacks·2mo ago
News Placeholder
Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest
Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 529,786...
MarketBeat·2mo ago
News Placeholder
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen downgraded Actuate Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher - Here's What Happened
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher - Time to Buy...
MarketBeat·3mo ago
News Placeholder
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU
Voss Capital LP grew its position in Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 101.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 286,140...
MarketBeat·4mo ago
News Placeholder
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%
The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4mo ago
<
1
2
...
>

Latest ACTU News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.